Aura Biosciences, Inc. (NASDAQ:AURA – Get Free Report) CFO Julie B. Feder sold 25,131 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $12.03, for a total value of $302,325.93. Following the completion of the transaction, the chief financial officer now directly owns 134,276 shares in the company, valued at $1,615,340.28. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Aura Biosciences Stock Performance
NASDAQ:AURA opened at $11.40 on Thursday. The firm’s 50-day moving average is $8.87 and its 200-day moving average is $8.15. Aura Biosciences, Inc. has a 52-week low of $5.99 and a 52-week high of $12.38. The company has a market cap of $564.79 million, a price-to-earnings ratio of -6.13 and a beta of 0.37.
Aura Biosciences (NASDAQ:AURA – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.04. Equities analysts predict that Aura Biosciences, Inc. will post -1.7 EPS for the current year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
AURA has been the topic of a number of recent analyst reports. HC Wainwright lifted their price target on shares of Aura Biosciences from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, October 18th. BTIG Research lifted their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Cowen restated a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Evercore ISI raised Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $23.00.
About Aura Biosciences
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Recommended Stories
- Five stocks we like better than Aura Biosciences
- The 3 Best Blue-Chip Stocks to Buy Now
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- What is Forex and How Does it Work?
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Using the MarketBeat Dividend Tax Calculator
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.